Sandoz — CureCurrent

Published trials44

Recruiting shown0

Roles1

SourceClinicalTrials.gov

Clinical trials

44 shown

Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With AsthmaNCT07223294 · lead sponsor · 2026-04-21

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisNCT06847724 · lead sponsor · 2025-06-10

ACTIVE_NOT_RECRUITING

A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)NCT06159790 · lead sponsor · 2024-04-29

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast CancerNCT05258747 · lead sponsor · 2022-04-07

An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.NCT04183634 · lead sponsor · 2019-12-03

Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid ArthritisNCT02744755 · lead sponsor · 2016-03-31

GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®NCT02514772 · lead sponsor · 2015-07-01

Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid ArthritisNCT02638259 · lead sponsor · 2015-02-21

Remission of ICD by Switching Dopamine Agonist to Levodopa/CarbidopaNCT01683253 · lead sponsor · 2012-11-01

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®NCT01735175 · lead sponsor · 2012-06-01

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-FilgrastimNCT01516736 · lead sponsor · 2012-03-01

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's DiseaseNCT01673724 · lead sponsor · 2012-02-01

Phase III Study Comparing the Efficacy and Safety of EP2006 and FilgrastimNCT01519700 · lead sponsor · 2011-12-01

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard TherapyNCT01274182 · lead sponsor · 2011-01-01

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating FactorNCT01459653 · lead sponsor · 2010-03-01

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product AdvairNCT00927758 · lead sponsor · 2009-06-01

Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting ConditionsNCT00959335 · lead sponsor · 2006-08-01

Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fed ConditionsNCT00865618 · lead sponsor · 2006-06-01

Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fasting ConditionsNCT00865176 · lead sponsor · 2006-06-01

Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed ConditionsNCT00960310 · lead sponsor · 2006-06-01

A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting ConditionsNCT00865033 · lead sponsor · 2005-11-01

To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting ConditionsNCT00946621 · lead sponsor · 2004-10-01

To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting ConditionsNCT00946465 · lead sponsor · 2004-10-01

To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting ConditionsNCT00946686 · lead sponsor · 2002-09-01

Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)NCT00959439 · lead sponsor · 2002-03-01

To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting ConditionsNCT00882882 · lead sponsor · 2001-06-01

To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mgNCT00946725 · lead sponsor · 2000-11-01

To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablet Under Fasting and FedNCT00883506 · lead sponsor · 2000-05-01

To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting ConditionsNCT00883064 · lead sponsor · 2000-03-01

Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting ConditionsNCT00960245 · lead sponsor · 1994-07-01

To Demonstrate the Effect of Food on the Bioavailability of GlipizideNCT00947024 · lead sponsor · 1993-11-01

To Demonstrate the Relative Bioequivalency Comparing Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol TabletsNCT00946504 · lead sponsor · 1992-10-01

To Demonstrate the Relative Bioavailability of Atenolol TabletsNCT00913965 · lead sponsor · 1989-07-01

To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal VolunteersNCT00946491 · lead sponsor · 1987-04-01

A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or ViruriaNCT00002268 · lead sponsor

An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and LeukopeniaNCT00002008 · lead sponsor

A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to AzidothymidineNCT00002263 · lead sponsor

A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and FeasibilityNCT00002006 · lead sponsor

A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With CytopeniaNCT00002258 · lead sponsor

A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.NCT00002253 · lead sponsor

A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and LeukopeniaNCT00002007 · lead sponsor

A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related DiarrheaNCT00002252 · lead sponsor

A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV RetinitisNCT00002016 · lead sponsor

A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and LeukopeniaNCT00002009 · lead sponsor

Sponsor roles

lead sponsor44

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.